Model of care for women at increased risk of breast and ovarian cancer

Maturitas

Volumn 71, Issue 1, 2012, Pages 3-5

  De Bock, Geertruida H ^a   Hesselink, Jan Willem ^a   Roorda, Carriene ^a   De Vries, Jaap ^a   Hollema, Harry ^a   Jaspers, Jan P C ^a   Kok, Theo ^a   Werker, Paul M N ^a   Oosterwijk, Jan C ^a   Mourits, Marian J E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER CENTER; CANCER RISK; CANCER SCREENING; DATA BASE; EDITORIAL; FAMILY HISTORY; FAMILY PLANNING; FEMALE; GENE MUTATION; GENETIC COUNSELING; HEALTH CARE QUALITY; HOSPITAL INFORMATION SYSTEM; HUMAN; MASTECTOMY; MODEL; NETHERLANDS; OVARY CANCER; PATIENT CARE; PATIENT REFERRAL; PHYSICIAN; PSYCHOLOGIST; RISK ASSESSMENT; SALPINGOOOPHORECTOMY; TUMOR SUPPRESSOR GENE; UNIVERSITY HOSPITAL;

BREAST NEOPLASMS; DELIVERY OF HEALTH CARE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OVARIAN NEOPLASMS; PATIENT CARE;

EID: 84855425461     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2011.10.008     Document Type: Editorial

References (31)

1. E.B. Claus, N. Risch, and W.D. Thompson Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction Cancer 73 1994 643 651 (Pubitemid 24046606)
2. A. Antoniou, P.D. Pharoah, and S. Narod Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 2003 1117 1130 (Pubitemid 36530000)
3. S. Chen, and G. Parmigiani Meta-analysis of BRCA1 and BRCA2 penetrance J Clin Oncol 25 2007 1329 1333 (Pubitemid 46706879)
4. D.H. Roukos, and E. Briasoulis Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome Nat Clin Pract Oncol 4 2007 578 590 (Pubitemid 47534757)
5. M.C. King, J.H. Marks, and J.B. Mandell Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 2003 643 646 (Pubitemid 37310920)
6. K. Anderson, J.S. Jacobson, and D.F. Heitjan Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation Ann Intern Med 144 2006 397 406 (Pubitemid 46768161)
7. M.S. Van Roosmalen, P.F. Stalmeier, and L.C. Verhoef Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers J Clin Oncol 22 2004 3293 3301 (Pubitemid 41103685)
8. S.L. Spear, M.E. Carter, and K. Schwarz Prophylactic mastectomy: indications, options, and reconstructive alternatives Plast Reconstr Surg 115 2005 891 909 (Pubitemid 40316435)
9. S.M. Domchek, T.M. Friebel, and S.L. Neuhausen Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study Lancet Oncol 7 2006 223 229 (Pubitemid 43286452)
10. M.J. Mourits, and G.H. de Bock Managing hereditary ovarian cancer Maturitas 64 2009 172 176
11. M.J. Kenkhuis, G.H. de Bock, and P.O. Elferink Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers Maturitas 66 2010 310 314
12. C. Buijs, C.H. Mom, and P.H. Willemse Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study Breast Cancer Res Treat 115 2009 573 580
13. J.B. Madalinska, J. Hollenstein, and E. Bleiker Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer J Clin Oncol 23 2005 6890 6898
14. J.B. Madalinska, M. van Beurden, and E.M. Bleiker The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy J Clin Oncol 24 2006 3576 3582 (Pubitemid 46630529)
15. Introduction of managed clinical networks within the NHS in Scotland. NHS MEL (Management Executive Letter) 10. Edinburgh, UK: St Andrews House; 1999.
16. A. Gregor Managed clinical network in practice - is it working? Clin Oncol (R Coll Radiol) 15 2003 169 171 (Pubitemid 36722759)
17. D.M. van der Kolk, G.H. de Bock, and B.K. Leegte Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age Breast Cancer Res Treat 124 2010 643 651
18. A.J. Rijnsburger, I.M. Obdeijn, and R. Kaas BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC screening study J Clin Oncol 28 2010 5265 5273
19. E.B. Gómez García, J.C. Oosterwijk, and M. Timmermans A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history Breast Cancer Res 11 2009 R8
20. L. Mohammadi, M.P. Vreeswijk, and R. Oldenburg A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example BMC Cancer 9 2009 211
21. B. Leegte, A.H. Van der Hout, and Deffenbaugh Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations J Med Genet 42 2005 e20
22. D. Bodmer, M.J. Ligtenberg, and A.H. van der Hout Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models Br J Cancer 95 2006 757 762 (Pubitemid 44373493)
23. L.C. Verhoog, A.M. van den Ouweland, and E. Berns Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families Eur J Cancer 37 2001 2082 2090 (Pubitemid 32938113)
24. N.M. van der Velde, M.J. Mourits, and H.J. Arts Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer 124 2009 919 923
25. B.B. Hermsen, R.I. Olivier, and R.H. Verheijen No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study Br J Cancer 96 2007 1335 1342 (Pubitemid 46685786)
26. H.F. Vasen, E. Tesfay, and H. Boonstra Early detection of breast and ovarian cancer in families with BRCA mutations Eur J Cancer 41 2005 549 554 (Pubitemid 40292734)
27. M. Kriege, C.T. Brekelmans, and I.M. Obdeijn Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer Breast Cancer Res Treat 100 2006 109 119
28. M. Kriege, C.T. Brekelmans, and H. Peterse Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer Breast Cancer Res Treat 102 2007 357 363 (Pubitemid 46474846)
29. M. Kriege, C.T. Brekelmans, and C. Boetes Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition N Engl J Med 351 2004 427 437
30. C.F. Ockhuysen-Vermey, L. Henneman, and C.J. Van Asperen Design of the BRISC study: a multicentre controlled clinical trial to optimize the communication of breast cancer risks in genetic counselling BMC Cancer 8 2008 283
31. J. Vos, A.M. Stiggelbout, and J. Oosterwijk A counselee-oriented perspective on risk communication in genetic counseling: explaining the inaccuracy of the counselees' risk perception shortly after BRCA1/2 test result disclosure Genet Med 13 2011 800 811